Volume Spike: Theravance (THRX)

Posted in General 
November 19th, 2008

Theravance, Inc. (NASDAQ: THRX) is about to re-open for trading after its stock was halted all day during the FDA PANEL REVIEW.  This stock is set to resume at 3:00 PM EST. Shares are indicated higher after a $6.72 close yesterday and its 52-week trading range is $5.34 to $26.09.  Count on high trading volume.

Its telavancin received a favorable recommendation from the Anti-Infective Drugs Advisory Committee (AIDAC) of the Food and Drug Administration for the proposed indication to treat complicated skin and skin structure infections (cSSSIs) caused by Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).

The Committee voted 21 to 5 that the data presented demonstrate the safety and effectiveness of telavancin for treatment of cSSSIs.

Jon C. Ogg
November 19, 2008

Comments are closed

-->